CMS signed a distribution agreement with Novartis for the ophthalmic drugs Nofluprednate® and Bevacizumab®
CMS has signed a distribution agreement with Novartis to obtain exclusive import, distribution, sales, and promotion rights for Ranibizumab Injection (Lucentis®) and Brolucizumab Injection (Beovu®) in mainland China. The cooperation period is five years, with Novartis responsible for production and supply. This move will enhance CMS's competitiveness in the ophthalmology field, integrate market channels and academic resources, and is expected to have a positive impact on the group's performance
According to the announcement from Kangzhe Pharmaceutical (00867), on October 27, 2025, the group signed a distribution agreement with Novartis Pharma Services AG for the injection of Leber's congenital amaurosis (trade name: Nucala) and the injection of Brolucizumab (trade name: Beovu).
Under the agreement, the group obtains exclusive import, distribution, sales, and promotion rights for the products in mainland China; Novartis will continue to be responsible for the production and supply of the products. The cooperation period is five years from the effective date specified in the agreement.
Novartis is a globally renowned pharmaceutical company headquartered in Basel, Switzerland. Novartis focuses on four core therapeutic areas with urgent patient needs (cardiovascular, renal and metabolic, oncology, immunology, and neuroscience) and five key technology platforms (chemotherapy, biotherapy, xRNA therapy, radioligand therapy, and gene and cell therapy).
This cooperation will enhance the overall competitiveness of the group's ophthalmology business company, Kangzhe Weisheng, in the ophthalmology field. Kangzhe Weisheng has covered areas such as retinal diseases, visual fatigue, and glaucoma. With the addition of Nucala and Beovu, there will be a high degree of synergy with the exclusive drug, Sitravatinib eye drops (Digoxin eye drops), and the exclusive medical device, EyeOP1 glaucoma treatment device, in terms of customer, expert resources, and channel networks, enhancing Kangzhe Weisheng's academic brand competitiveness in the ophthalmology field, providing positive momentum for continuous cooperation and the development of clinically needed innovative ophthalmic products, and offering more diversified treatment options for patients with ophthalmic diseases. At the same time, Kangzhe Weisheng's professional ophthalmology team will integrate market channels and academic resources to enhance the overall efficiency of the team, and it is expected to have a positive impact on the group's performance
